BioSpace News Archive

ixlayer, a leader in technology-based solutions for diagnostic testing, unveiled multi-lingual support for COVID-19 testing, vaccine distribution and monitoring.

AEVOLVE is excited to announce that P2PB2B, one of the world’s fastest growing technological exchanges, has listed AEVOLVE’s AVEX medical blockchain token

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Health Canada has authorized its vaccine against COVID-19 for the immunization of people 18 years of age and older under an Interim Order.

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, announces its financial calendar for the year 2021.

Governor Northam and the Virginia Biotechnology Association announced today that GO Virginia has approved a competitive grant request to help fund Virginia Bio-Connect, a $3.2 million Statewide industry cluster scale up initiative. The project, directed by the Virginia Biotechnology Association, is a multi-regional collaboration designed to increase connectivity and awareness of the existing programs, resources, and commun

At the request of IIROC, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) wishes to confirm that the Company’s management and Board of Directors are unaware of any material change in the Company’s operations that would account for the recent increase in market activity. About Acasti Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescript

Botanical Solution Inc. (BSI), innovator of sustainable, highly consistent and cost effective Advanced Botanical Materials, has successfully secured $3.3 million in a seed round of funding, and is planning another round of funding for Spring 2021. The Spring 2021 Round of funding will boost BSI’s proven ability to discover and develop novel botanical products that are sustainable, highly consistent and cost effective.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) to the U.S. Food and Drug Administration (FDA). The NDA for VP-102 was resubmitted based on the outcome and final minutes of a Type A meeting

Urovant Sciences Announces U.S. FDA Approval of GEMTESA ® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB) GEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences U.S. commercial launch planned in late-Q1 2021 IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urovant Sciences (Nasdaq: UROV) announced today that th

Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, today announced that its Board of Directors has authorized a stock repurchase program, under which the Company may repurchase up to $100 million of its outstanding common stock through December 31, 2021. Scott Ginn, Chief Financial Officer, stated, “Given our strong cashflow and low leverage, we feel it is prudent to have authorizati